Patents by Inventor Biliang HU

Biliang HU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
    Publication number: 20240141292
    Abstract: A population of immune cells comprising modified immune cells with reduced inflammatory properties, wherein such modified immune cells may have reduced production of one or more inflammatory cytokines (e.g., interleukin 2), and/or express one or more antagonists of one or more inflammatory cytokines (e.g., interleukin 6). Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases or immune diseases).
    Type: Application
    Filed: January 11, 2024
    Publication date: May 2, 2024
    Applicant: HUNAN SIWEIKANG THERAPEUTICS CO. LTD
    Inventor: Biliang Hu
  • Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
    Patent number: 11965176
    Abstract: A population of immune cells comprising modified immune cells with reduced inflammatory properties, wherein such modified immune cells may have reduced production of one or more inflammatory cytokines (e.g., interleukin 2) and/or express one or more antagonists of one or more inflammatory cytokines (e.g., interleukin 6). Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases or immune diseases).
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: April 23, 2024
    Assignee: HUNAN SIWEIKANG THERAPEUTICS CO. LTD
    Inventor: Biliang Hu
  • GENETICALLY MODIFIED IMMUNE CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND HAVING REDUCED PROINFLAMMATORY CYTOKINE SIGNALING
    Publication number: 20230149465
    Abstract: A population of immune cells comprising modified immune cells co-expressing a chimeric antigen receptor comprising, inter alia, an IB-2K? cytoplasmic signaling domain. Also provided herein are genetically engineered immune cells having reduced production of interferon gamma (IFNy). Such genetically engineered immune cells may have a disrupted endogenous IFNy gene, a disrupted endogenous IFNy receptor (IFNyR) gene, or both. Alternatively, the immune cells may express an IFNy antagonist.
    Type: Application
    Filed: April 6, 2021
    Publication date: May 18, 2023
    Inventor: Biliang HU
  • MODIFIED IMMUNE CELLS CO-EXPRESSING CHIMERIC ANTIGEN RECEPTOR AND IL-6 ANTAGONIST FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
    Publication number: 20220096548
    Abstract: A population of immune cells comprising modified immune cells co-expressing a chimeric antigen receptor and an IL-6 signaling antagonist (e.g., an anti-IL6 or anti-IL-6R antibody) and optionally an IL-1 signaling antagonist. Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases, or immune diseases).
    Type: Application
    Filed: January 6, 2020
    Publication date: March 31, 2022
    Inventor: Biliang HU
  • MODIFICATION OF IMMUNE CELLS FOR REDUCING TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
    Publication number: 20210009951
    Abstract: A population of immune cells comprising modified immune cells with reduced inflammatory properties, wherein such modified immune cells may have reduced production of one or more inflammatory cytokines (e.g., interleukin 2) and/or express one or more antagonists of one or more inflammatory cytokines (e.g., interleukin 6). Also provided herein are methods of producing such immune cell populations comprising the modified immune cells and methods of using such in cell therapy (e.g., to treat cancer, infectious diseases or immune diseases).
    Type: Application
    Filed: March 13, 2019
    Publication date: January 14, 2021
    Applicant: Celledit LLC
    Inventor: Biliang HU